


## (E)-Akt inhibitor-IV

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-14971   |
| CAS No.:           | 959841-49-7  |
| Molecular Formula: | C <sub>31</sub> H <sub>27</sub> IN <sub>4</sub> S  |
| Molecular Weight:  | 614.54   |
| Target:            | Akt  |
| Pathway:           | PI3K/Akt/mTOR  |
| Storage:           | -20°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

|   |   |                       |      |           |           |           |            |
|---|---|-----------------------|------|-----------|-----------|-----------|------------|
| In Vitro  | DMSO : 50 mg/mL (81.36 mM; Need ultrasonic)   |                       |      |           |           |           |            |
|   | Preparing Stock Solutions   | Solvent Concentration | Mass | 1 mg      | 5 mg      | 10 mg     |            |
|   |   |                       |      | 1 mM      | 1.6272 mL | 8.1362 mL | 16.2723 mL |
|   |   |                       |      | 5 mM      | 0.3254 mL | 1.6272 mL | 3.2545 mL  |
| 10 mM   |   |                       |      | 0.1627 mL | 0.8136 mL | 1.6272 mL |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                       |      |           |           |           |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: ≥ 2 mg/mL (3.25 mM); Clear solution |                       |      |           |           |           |            |

### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | (E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor, with potent cytotoxic <sup>[1]</sup> .   |
| IC <sub>50</sub> & Target | Akt <sup>[1]</sup>   |
| In Vitro                  | (E)-Akt inhibitor-IV (compound 7) exhibits average GI <sub>20</sub> of 0.04 μM on four cell lines (MDA-MB468 cells, MDA-MB231 cells, MCF7 cells and 184B5 cells) <sup>[1]</sup> .<br>(E)-Akt inhibitor-IV shows little effects on the growth of 184B5 non-cancer cells at the average GI <sub>20</sub> doses <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### CUSTOMER VALIDATION

- 
- Leuk Res Rep. 2023 Mar 22;128:107059.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Changkun Hu, et al. A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur J Med Chem. 2010 Feb;45(2):705-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA